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Abstract
Background: Understanding the earliest pathophysiological changes of Alzheimer’s disease (AD) may aid in the
search for timely diagnostic biomarkers and effective disease-modifying therapies. The p53 protein is mostly known
for its role in tumor suppression. However, emerging evidence supports that dysregulated p53 activity may
contribute to various peripheral and brain alterations during the earliest stages of AD. This review describes the
mechanisms through which p53 dysregulation may exacerbate AD pathology and how this could be used as a
potential peripheral biomarker for early detection of the disease.
Main body: p53, known as the guardian of the genome, may underlie various compensation or defense mechanisms
that prevent neurons from degeneration. These mechanisms include maintenance of redox homeostasis, regulation of
inflammation, control of synaptic function, reduction of amyloid β peptides, and inhibition of neuronal cell cycle re-entry.
Thereby, dysregulation of p53-dependent compensation mechanisms may contribute to neuronal dysfunction, thus
leading to neurodegeneration. Interestingly, a conformational misfolded variant of p53, described in the literature as
unfolded p53, which has lost its canonical structure and function, was observed in peripheral cells from mild cognitive
impairment (MCI) and AD patients. In AD pathology, this peculiar conformational variant was caused by post-translational
modifications rather than mutations as commonly observed in cancer. Although the presence of the conformational
variant of p53 in the brain has yet to be formally demonstrated, the plethora of p53-dependent compensation
mechanisms underscores that the guardian of the genome may not only be lost in the periphery during AD pathology.
Conclusion: These findings revisit the role of p53 in the early development and exacerbation of AD pathology, both in
the brain and periphery. The conformational variant of p53 represents a potential peripheral biomarker that could detect
AD at its earliest stages.
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Background
Alzheimer’s disease (AD) spans a clinical continuum
from normal cognition to irreversible cognitive impair-
ment, accounting for 60 to 80% of dementias [1, 2]. The
disease constitutes a serious health concern in the aging
population with a rapidly growing socio-economic bur-
den [3]. The worldwide economic costs associated with
dementia, which consist of direct medical, direct social
sector, and informal care costs, increased by 35% between
2010 and 2015 and are estimated to rise to USD 2 trillion
by 2030 [3]. A growing body of evidence demonstrates
that the pathophysiological features of AD have an onset
decades before the first symptoms appear [4, 5]. During
this preclinical stage, compensation or defense mecha-
nisms, such as the DNA damage response, may initially
overcome the alterations in the brain, preventing cognitive
decline [6]. Some of these defense mechanisms may be
dependent on p53, also known as the guardian of the gen-
ome [7]. The role of p53 beyond tumor suppression has
been well established in recent years, demonstrating that
dysregulated p53 signaling contributes to different path-
ologies including diabetes, obesity, and aging-associated
neurodegenerative disorders [8]. Dependent on the stress
stimulus, cell type, and context, p53 regulates the decision
between life and death by either inducing apoptosis or by
preventing and repairing cellular damage [8, 9]. A non-
systematic review of the literature was performed, using
the National Library of Medicine’s PubMed database up
to October 2020, to collect evidence on the possible role
of p53 in the pathogenesis of AD aiming to describe how
dysregulated p53 signaling may exacerbate AD pathology,
while holding promise as an early predictive peripheral
biomarker of the disease.
AD beyond amyloid and tau pathology
For almost 20 years, the amyloid hypothesis has been
regarded as the most important driver of the pathogen-
esis of AD. According to this hypothesis, amyloid β (Aβ)
peptides accumulate during the process of aging forming
Aβ fibrils and ultimately senile plaques. This was sup-
ported by the fact that in less than 1% of cases, AD is
caused by specific mutations in three genes. These genes
are coding for amyloid-precursor protein (APP), Preseni-
lin 1 (PS1), and Presenilin 2 (PS2) which are all linked to
Aβ metabolism [10]. However, the amyloid hypothesis
has come under scrutiny because immunotherapies tar-
geting Aβ failed to improve clinical outcomes in patients
with mild-to-moderate AD [11–13]. It is currently un-
known, if failure could be attributed to late diagnosis of
patients with already severe neuronal loss or if amyloid
is not the only target to fight in AD. As demonstrated
by positron emission tomography, tau accumulation is
pathologically more relevant than the formation of
amyloid plaques [10]. In the AD brain, tau becomes
hyperphosphorylated leading to the formation of neuro-
fibrillary tangles (NFTs). By destabilizing microtubules,
these NFTs cause neuronal cell death and neurodegen-
eration, correlating with cognitive decline and dementia
in AD patients [10]. However, other pathophysiological
processes, including accumulation of oxidative stress,
induction of a pro-inflammatory environment, and
neuronal cell cycle re-entry, may precede the onset of
amyloid and tau pathology.
Oxidative stress, which is the result of an imbalance
between reactive oxygen species (ROS) and the activity
of antioxidant enzymes, was found to be one of the earli-
est events contributing to synaptic impairment in AD
[5]. Aβ and AD risk factors, such as advanced age and
apolipoprotein E ε4 (ApoEε4), can all exacerbate oxida-
tive stress [14]. Accordingly, increased markers of oxida-
tive and nitrosative stress have been found in different
post-mortem brain regions of patients with AD [15].
Furthermore, oxidative stress can induce tau hyperpho-
sphorylation, suggesting that indeed oxidative stress is
an early event in the establishment of neurodegeneration
[14, 16].
Besides oxidative stress, the presence of immune-
related antigens and cells around amyloid plaques in the
brains of patients with AD has been reported since the
1980s [17–19]. Both amyloid and tau pathology may be
exacerbated by chronic activation of microglia, astro-
cytes, and other immune cells. This is further supported
by emerging evidence demonstrating that mutations in
microglia-specific receptors significantly increase the risk
of developing AD [20]. Research is currently aiming to
disentangle the exact pathophysiological mechanisms of
inflammation in AD to understand how neuroinflamma-
tion may predispose patients to develop AD.
Lastly, evidence for neuronal cell cycle re-entry has
been known since the mid-1990s when several phospho-
epitopes characteristics of dividing cells were discovered
in the AD brain but not in age-matched controls [21].
Already during the earliest stages of AD, post-mitotic
neurons re-enter the cell cycle, following either apop-
tosis or DNA synthesis similarly leading to cell death be-
fore cell division [22, 23]. The cell cycle hypothesis,
therefore, explains the rather slow rate of atrophy during
the progression of AD. The chapters below aim to de-
scribe how dysregulation of p53 activity may underlie
these different pathophysiological mechanisms and com-
pile the evidence that p53 signaling is indeed compro-
mised in patients progressing to AD.
p53 and its isoforms: regulators of aging and
neuroinflammation?
Tight control of p53 activity is paramount for healthy
aging. In fact, aberrant regulation of its activity can con-
tribute to a broad spectrum of pathological conditions,
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spanning from accelerated aging to tumorigenesis due to
excessive activation or inactivation, respectively (reviewed
in [8, 24, 25]). The pleiotropic role of p53 in health and dis-
ease is dependent on the expression of at least 12 protein
isoforms in addition to the expression of the full-length p53
protein [26]. Mice studies have shown that the longevity-
assurance activity of p53 depends on the levels of an N-
terminally truncated p53 isoform (Δ40p53 or p44) [27, 28].
Overexpression of this isoform in mice induced accelerated
aging and aggregation of tau in NFTs, which together with
hyperactivation of the insulin-like growth factor signaling
network caused synaptic deficits and cognitive decline,
characteristic of AD [27, 28]. An additional study delineated
that the Δ40p53 isoform was generated through alternative
splicing in transgenic mice overexpressing the short cyto-
solic APP intracellular domain (AICD) peptide, which is an
important transcriptional regulator of genes involved in AD
pathogenesis [29, 30]. Furthermore, studies have shown
that this isoform is activated in an age-dependent fashion
in the mouse brain coinciding with an increase in phos-
phorylated tau [28]. As transgenic mouse models only re-
capitulate parts of the pathogenesis of AD, brain tissues of
late-onset sporadic AD (sAD) patients were examined for
the presence of the Δ40p53 isoform. Levels of the Δ40p53
isoform were only slightly but not significantly increased in
these post-mortem brain tissues [29]. However, results
from brain tissues may have been confounded by intrinsic
subject variability and severe neurodegeneration, not com-
pletely excluding that this p53 isoform may contribute to
the formation of NFTs, neurodegeneration, and accelerated
aging in patients progressing to AD [29].
More recently, an imbalance between the expression of
two different p53 isoforms was found in senescent astro-
cytes, which were more abundantly present in brain tissues
from AD patients compared with controls [26]. These senes-
cent astrocytes expressed higher levels of the senescence-
promoting p53β isoform in comparison with the Δ133p53
isoform, which modulates full-length p53 activity. The im-
balance between these two isoforms was found to regulate
the neurotoxic function of astrocytes by promoting the
senescence-associated secretory phenotype which involves
secretion of pro-inflammatory cytokines, such as interleukin-
6 [26]. Possibly, shifting the balance towards higher activity
of the Δ133p53 isoform in astrocytes could induce their neu-
roprotective function again, inhibiting or delaying the pro-
gression of AD [26]. More research will be needed to
understand if an imbalance in the normal ratio of p53 and
its isoforms may contribute to the development of AD by ac-
celerating aging and exacerbating neuroinflammation.
Dysregulation of p53-induced adaptive responses in the
AD brain
Besides polymorphisms and isoforms, the biological
function of p53 is mainly regulated by protein-protein
interactions and by a complex plethora of post-translational
modifications, including phosphorylation, acetylation, and
methylation [9]. These post-translational modifications sub-
sequently orchestrate p53-induced adaptive responses,
some of which may become gradually dysregulated during
the continuum of AD. Upon genotoxic stress, the stability
of p53 can be increased by multiple kinases, including
ataxia-telangiectasia mutated (ATM) and ATR (ATM
Rad3-related) protein kinases, checkpoint kinase 1/2
(Cdk1/Cdk2), and DNA-dependent protein kinase (DNA-
PK) [31, 32]. Phosphorylation of p53 by one of the above-
mentioned kinases disrupts the p53-mouse double minute
2 (MDM2) interaction, alleviating proteasomal p53 degrad-
ation [32]. This cellular defense mechanism becomes acti-
vated under conditions of mild or subacute genotoxic stress
to promote repair of DNA mutations, which naturally
occur during the aging process [31]. Interestingly, micro-
array analysis revealed that expression of the ATM protein
kinase was higher in the superior temporal cortex of AD
patients with mild (Clinical Dementia Rating [CDR 0.5–1])
and moderate to severe (CDR 2–5) dementia compared
with non-demented controls (CDR 0). Accordingly, the
gene expression levels of the ATM protein kinase correlated
with neuritic plaque density and Braak neuropathological
stages [33]. The DNA damage response, therefore, appears
to be one of the defense mechanisms that is triggered dur-
ing the progression of AD, resulting in p53 activation
(Fig. 1).
DNA damage is often the result of oxidative stress. Under
conditions of low and subacute oxidative stress, p53 en-
sures cell survival by activating several antioxidant genes,
such as manganese superoxide dismutase (MnSOD) and
TP53-induced glycolysis and apoptosis regulator (TIGAR)
[31, 34]. However, the p53-induced antioxidant response
seems to be impaired in patients with AD. This finding was
supported by low MnSOD expression in primary neurons
isolated from an AD mouse model carrying mutations in
APP and PS1 [35]. As MnSOD is a direct p53 target, this
gradual dysregulation of the antioxidant defense during the
disease continuum may be caused by impaired p53 activity
(Fig. 1).
Additionally, human studies have confirmed that p53-
mediated antioxidant responses are altered in post-
mortem brain tissues derived from patients with AD.
The metabolic pentose phosphate pathway (PPP) is
known to be essential for the survival of neurons to cope
with elevated production of ROS [36]. As mentioned
earlier, p53 can activate TIGAR, which ensures the activ-
ity of the PPP, protecting neurons against stress-induced
changes [34, 36]. However, the expression of TIGAR was
inversely correlated with the severity of AD dementia
[33]. Although not confirmed in human studies, dysreg-
ulation of p53 signaling in the AD brain may be respon-
sible for the downregulation of TIGAR seen in the
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superior temporal cortex of AD patients with mild (CDR
1) and severe (CDR 5) dementia (Fig. 1).
As mitochondria are the main producers of ROS,
maintaining their function and viability is of the utmost
importance. p53 can preserve mitochondrial function by
regulating mitochondrial biogenesis, removing non-
functional mitochondria, maintaining redox homeostasis,
and controlling metabolism [36]. Dependent on the cell
type and stimulus, p53 can either induce or repress per-
oxisome proliferator-activated receptor-c coactivator-1a
(PGC-1α), which is a known inducer of mitochondrial
biogenesis [36]. Interestingly, activation of PGC-1α by
p53 was demonstrated in neuroblastoma cells upon de-
pletion of glutathione. Surprisingly, this activation did
not increase mitochondrial biogenesis but induced an
antioxidant response [37]. This p53-induced antioxidant
response may also be neuroprotective in vivo, as gluta-
thione was found to be decreased in the hippocampi of
patients with mild cognitive impairment (MCI) (CDR
0.7 and Mini-Mental State Examination [MMSE]: 25.5)
and AD (CDR 1.5 and MMSE: 18.4). The study con-
firmed that this decrease in glutathione was not attrib-
uted to tissue atrophy [38]. Furthermore, the reduced
glutathione levels significantly correlated with the degree
of cognitive impairment. Interestingly, also PGC-1α ex-
pression was found to decrease with the severity of de-
mentia when examining the hippocampi of AD patients
with different neuritic plaque and AβX-42 contents.
These findings again imply that loss of the p53-induced
adaptive response is involved in the exacerbation of oxi-
dative stress early on during the progression of AD [39]
(Fig. 1). As a result of increased oxidative stress, pro-
inflammatory genes may be induced, shifting the im-
mune balance towards a pro-inflammatory phenotype
[40]. Emerging evidence suggests that also p53 itself may
modulate the pro-inflammatory environment [41], but
the exact implications for AD remain to be deciphered.
Although the above-described evidence suggests that
impairment of p53-induced adaptive responses are associ-
ated with neurodegeneration observed in AD, the link be-
tween the neuroprotective effects of p53 and AD remains
controversial. This is mostly due to studies which have
demonstrated that p53 is accountable for neurodegenera-
tion due to induction of neuronal apoptosis. In vitro experi-
ments have shown that pro-apoptotic p53 target genes are
triggered upon exposure of cells to excessive levels of geno-
toxic/oxidative stress or micromolar Aβ concentrations [42,
43]. However, neurodegeneration in AD is not the result of
a single acute toxic insult and subsequent apoptosis, but ra-
ther due to chronic subtoxic oxidative stress insults
(reviewed in [44]), resulting in the progressive loss of com-
pensatory mechanisms, such as the p53-induced antioxi-
dant response. Therefore, the role of p53 in AD pathology
may need to be revisited, as dysregulation of p53 activity
Fig. 1 Exacerbation of AD pathology through gradual dysregulation of p53-induced adaptive responses. Upon chronic exposure to mild/subacute
stress, p53 becomes activated through ROS or through the induction of DNA damage sensing genes, such as ATM kinase. Following p53
activation, several antioxidant genes (e.g., TIGAR, MnSOD, and PGC-1α) are upregulated to subsequently restore cellular damage. In the AD brain,
levels of ATM are strongly upregulated. However, there appears to be a defect in the downstream canonical p53 pathway, as p53-induced
adaptive responses are progressively dysregulated during the continuum of the disease, exacerbating AD pathology. AD, Alzheimer’s disease;
ATM, ataxia-telangiectasia mutated; MnSOD, manganese superoxide dismutase; PGC-1α, peroxisome proliferator-activated receptor-c coactivator-
1a; TIGAR, TP53-induced glycolysis regulatory phosphatase; ROS, reactive oxygen species
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throughout the disease continuum may underlie the oxida-
tive stress hypothesis, which is known to be an early deter-
minant of the pathogenesis of AD [5].
Revisiting the p53-Aβ feedback loop in the AD brain
Abnormal activity of p53 may also affect other causal
paths in the development of AD (Fig. 2). Wild-type p53
is a well-known inhibitor of the mammalian target of
rapamycin (mTOR) signaling pathway, which is hyperac-
tivated in the brain and periphery before the AD demen-
tia stage [45–47]. In vitro experiments using primary
neuron cultures from mice have shown that hyperactiva-
tion of the mTOR signaling axis was in part mediated by
the accumulation of Aβ, which activates mTOR complex
1 (mTORC1) at the plasma membrane. Following activa-
tion, mTORC1 phosphorylates tau at a serine residue
that is required to induce aberrant cell cycle re-entry of
post-mitotic neurons [48]. Additionally, a study using an
AD transgenic mouse model found that buildup of Aβ
increased the activity of the mTOR pathway initiating a
negative feedback loop which reduced the clearance of
Aβ peptides by inhibiting autophagy [49]. As mentioned
earlier, mTOR signaling is also increased in human brain
samples of patients affected by amnestic MCI (soluble
Aβ1–42 concentration: 29.7 fmol/mg and MMSE: 23.3)
and AD (soluble Aβ1–42 concentration: 35.1 fmol/mg
and MMSE: 12.9) in comparison with healthy controls
(soluble Aβ1–42 concentration: 8.08 fmol/mg and MMSE:
28.7) [50]. Although not formally demonstrated in AD,
hyperactivation of the mTOR pathway may be caused by
dysregulated p53 signaling. If unfunctional p53 is unable
to repress mTOR signaling, this may lead to hyperactiva-
tion of the pathway with a concomitant inhibition of au-
tophagy and aberrant neuronal cell cycle, linking impaired
p53 signaling to both the amyloid and cell cycle hypothesis.
Furthermore, in vitro experiments showed that dysregu-
lated p53 signaling may upregulate beta-site APP-cleaving
enzyme 1 (BACE1), which is the rate-limiting enzyme in
the generation of Aβ. Interestingly, these in vitro experi-
ments demonstrated that transcription of BACE1 is re-
pressed by p53, protecting against Aβ accumulation [51].
This study, therefore, provided additional evidence that af-
fecting the transcriptional activity of p53 can directly im-
pact the amyloid cascade. Another p53-dependent causal
path that may play a role in the development of AD is the
downregulation of sirtuin 6 (SIRT6). SIRT6 promotes lon-
gevity by controlling DNA repair, genome integrity, energy
metabolism, and inflammation [52]. Reduced levels of
SIRT6 were observed in human brain samples of AD pa-
tients and the underlying mechanism was unveiled in the
HT-22 mouse hippocampal neuronal cell line. In this cell
line, Aβ42 post-transcriptionally reduced p53 protein levels,
followed by a decreased binding of p53 to the SIRT6 pro-
motor, downregulating the expression of this anti-aging
gene and subsequently compromising longevity [52].
A conformational change dysregulates p53 signaling in
AD
The above-described evidence is only speculating which
downstream p53 effectors could contribute to the pro-
gression of AD upon dysregulation of p53 activity. The
first evidence to prove that the activity of p53 is indeed
Fig. 2 The p53-Aβ feedback loop revisited. The p53 protein inhibits the amyloid cascade by repressing the transcription of BACE1. Additionally,
p53 inhibits the mTOR signaling pathway, resulting in Aβ protein clearance through the induction of autophagy. However, Aβ peptides may
prevent these neuroprotective p53 effects through posttranscriptional repression of p53, which leads to reduced binding of p53 to the promotor
of the anti-aging gene, SIRT6. Aβ, amyloid beta; AICD, amyloid precursor protein intracellular domain; APP, amyloid precursor protein; BACE1,
beta-site APP-cleaving enzyme 1; mTOR, mammalian target of rapamycin; sAPPβ, soluble amyloid precursor protein beta; SIRT6, sirtuin-6
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altered in AD was found in skin fibroblasts derived from
sAD patients [53]. Upon H2O2 exposure, fibroblasts
from sAD patients did not activate canonical p53-
dependent cell cycle regulator (p21 and GADD45) and
pro-apoptotic (BAX1) genes. This impairment resulted
in accelerated cell cycle re-entry, leading to diminished
H2O2-induced apoptosis in fibroblasts from sAD pa-
tients compared with those from non-AD controls [53].
Although these findings were not confirmed in neurons,
they were the first to demonstrate that p53-induced
DNA damage repair mechanisms are altered in periph-
eral cells from AD patients. Lack of p53 activation was
caused by a conformational change in its tertiary structure,
misfolding the protein and generating a conformational
variant of the p53 protein, which is transcriptionally in-
active on p21 and GADD45 promoters [54]. However, the
conformational change was not related to mutations, as
commonly is the case in tumor cells [55]. Interestingly, the
mutation-independent formation of the conformational
variant of the p53 protein was AD-specific, as in vitro
models (human embryonic kidney [HEK] and differentiated
neuroblastoma SHSY5Y cells) overexpressing the APP751
protein and exposure of fibroblasts from non-AD subjects
to nanomolar Aβ1–40 and Aβ1–42 concentrations induced
the conformational change in the p53 protein (Fig. 3) [56–
58]. Mechanistically, low intracellular amounts of soluble
Aβ peptides were shown to deregulate zyxin, which in turn
leads to proteasomal degradation of homeodomain inter-
acting protein kinase 2 (HIPK2) [57, 58]. Consequently,
downregulation of HIPK2 resulted in the upregulation of
metallothionein 2A (MT2A), inducing the conformational
variant of p53, which is described in the literature as un-
folded p53, by chelating the zinc atom that is responsible
for the wild-type p53 conformation [57]. Furthermore, pre-
treatment of HEK cells with an Aβ-sequestering antibody
or an antioxidant partially prevented the p53 conform-
ational change, implying important roles of both Aβ pep-
tides and the pro-oxidant environment in p53 misfolding
[56]. The pro-oxidant environment in immortalized lym-
phocytes derived from early-onset sAD and familial AD
(fAD) patients was shown to induce the p53 conform-
ational change, mainly due to nitration of its tyrosine resi-
dues (Fig. 3) [59]. Notably, the increase in unfolded p53
was a marker of impaired redox homeostasis due to its in-
verse correlation with SOD activity, considering peripheral
cells from amnestic MCI (CDR 0.5), severe AD (CDR 2),
and healthy subjects (CDR 0) [59, 60]. Concomitant with
the increase in unfolded p53, the expression of CD44 was
increased in lymphocytes from overt AD patients, which
may be of relevance for the immune crosstalk between the
periphery and brain in AD pathology [61]. Furthermore, a
conformational change in p53 rendered lymphocytes from
AD patients less sensitive to rapamycin-mediated inhibition
of mTOR signaling, resulting in G (1)/S checkpoint
Fig. 3 The unfolded p53 protein underlies various early hallmarks of AD pathology. Sublethal Aβ concentrations inhibit the Zyxin/HIPK2 signaling
axis, resulting in upregulation of MT2A. Following MT2A upregulation, zinc atoms are chelated which are necessary to maintain wild-type p53
conformation. In addition, chronic exposure to subtoxic nitrosative stress results in nitration of p53 tyrosine residues, misfolding the p53 protein,
and dysregulating its activity. An increase in unfolded p53 protein was directly linked to downregulation of SOD and GAP-43, and to upregulation
of CD44 and mTOR, potentially leading to impaired redox homeostasis, synaptic impairment, inflammation, and aberrant cell cycle, respectively.
Aβ, amyloid beta; GAP-43, growth-associated protein 43; HIPK2, homeodomain interacting protein kinase 2; MT2A, metallothionein 2A; mTOR,
mammalian target of rapamycin; ROS, reactive oxygen species; SOD, superoxide dismutase
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dysfunction [62]. This checkpoint dysfunction could reflect
aberrant neuronal cell cycle re-entry and supports the
above-described hypothesis that abnormal p53 activity
could contribute to dysregulated mTOR signaling in the
AD brain.
Although evidence remains scarce, some studies in-
dicate that the conformation of p53 is not only per-
turbed in peripheral cells but also in the brain
regions of AD patients. An experimental study, using
neuroblastoma differentiated neuron-like cells overex-
pressing APP, showed that unfolded p53 downregu-
lated growth-associated protein 43 (GAP-43), which is
involved in axonal outgrowth and synaptic plasticity
[63, 64]. It is indeed reported in post-mortem brain
studies that GAP-43 protein expression is decreased
in the frontal cortex of patients with AD [65, 66]. Al-
though these studies did not investigate the p53 path-
way, we can speculate that lack of p53 transcriptional
activity, due to its conformational changes, is respon-
sible for reduced GAP-43 expression in the AD brain.
Additional evidence in post-mortem brain tissues of
AD patients showed a huge amount of nitrated and
oxidized p53 [67], supporting the findings in immor-
talized lymphocytes from AD patients. The most
compelling evidence for a perturbation of p53 activity
in the AD brain was recently demonstrated by Farmer
et al. (2020) [68]. This study found that cytosolic p53
aggregates colocalized with tau protein in the frontal
cortex of AD patients (Braak stage 6) but not in age-
matched controls [68]. It will be interesting to deter-
mine in future studies if these p53 aggregates are
composed of unfolded p53. Unfolded p53 found in
peripheral cells may, therefore, be resembling loss of
p53 activity in the AD brain. If this would be the
case, unfolded p53 could be a marker of various early
AD pathophysiological mechanisms, such as impaired
redox homeostasis, neuronal cell cycle re-entry, in-
flammation, and synaptic deficits (Fig. 3).
Future perspectives
Unfolded p53: a putative peripheral biomarker for early
detection of AD
The assessment of biomarkers in peripheral cells and
biofluids, such as fibroblasts, lymphocytes, and plasma,
offers the advantage to be non-invasive and easily ac-
cessible compared to cerebrospinal fluid and imaging
biomarkers. A recent review identified that 34% of re-
ports on blood-based biomarkers were related to periph-
eral changes in emerging mechanisms, such as
mitochondrial respiration, inflammatory markers, and
oxidative stress response [69]. As described above, the
conformational change in p53 may underlie these mech-
anisms, which may occur early in the disease continuum,
supporting the use of unfolded p53 as a putative
biomarker for the diagnosis of AD before the onset of
cognitive decline. Indeed, initial studies found that the
unfolded p53 protein was able to discriminate AD pa-
tients from non-AD controls, due to a significantly
higher expression of this conformationally altered iso-
form in peripheral blood mononuclear cells (PBMCs)
from overt AD patients (CDR 1.5–2 and MMSE: 17)
[70–72]. In addition, the level of unfolded p53 was inde-
pendent of the APOE ε4 allele carrier status and was
also significantly increased in PBMCs derived from pre-
clinical patients with MCI compared with healthy con-
trols. Consequently, elevated levels of the unfolded p53
protein were found to be predictive of the conversion
from amnestic MCI to AD dementia [71–73]. Import-
antly, the unfolded p53 protein was differentially
expressed between AD patients and patients affected by
either Parkinson’s disease or other types of dementia,
confirming that the conformational change in p53 is in-
duced by an AD-specific mechanism [70]. What still
limits the general acceptance of p53 involvement in AD
is the undeniable reputation it has in cancer. To over-
come such view, a new antibody 2D3A8 able to identify
a p53 misfolded conformational variant that was found
to be highly expressed in AD has recently been devel-
oped [74]. This novel 2D3A8 antibody recognizes a lin-
ear epitope between the DNA binding domain and the
conjunction region with the tetramerization domain.
This epitope is less accessible when the protein is assem-
bled in its native form but most likely becomes exposed
due to redox post-translation modifications, as suggested
by the pro-oxidant environment in AD [74]. In addition,
preliminary studies found that the level of unfolded p53
protein detected by the 2D3A8 antibody in PBMCs cor-
related with age and cognitive impairment in AD [74].
Future longitudinal studies should aim to address
whether this peripheral biomarker correlates with the
deposition of amyloid and tau in the AD brain and con-
firm if unfolded p53 is able to diagnose AD at its early
stages, predicting if patients with MCI are predisposed
to develop AD.
Unfolded p53: a potential target for therapeutic monitoring
in AD
Considering the oxidative stress hypothesis as one of the
earliest mechanisms underlying AD, antioxidant therap-
ies have been studied for years. However, randomized
clinical trials examining the clinical benefits of antioxi-
dants, such as vitamin E supplementation, remain incon-
clusive. Despite the fact that vitamin E is significantly
lower in plasma and cerebrospinal fluid of patients with
AD compared to those without, vitamin E supplementa-
tion did not consistently halt cognitive decline in human
trials. One of the caveats of antioxidant supplementation
is the identification of appropriate oxidative stress
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markers for evaluation of its response [75]. As the un-
folded p53 conformation is induced by the pro-oxidant
environment [59], it has the potential to be one of these
oxidative stress markers that can be used for therapeutic
monitoring in studies evaluating the impact of antioxi-
dant therapies on the disease progression of AD. In fact,
in vitro studies have shown that the formation of the un-
folded p53 conformation is a dynamic process that is re-
versible by restoring the pro-oxidant environment [56].
Therefore, it would be interesting to examine how
disease-modifying drugs may influence the conformation
of p53 in the periphery and ultimately the brain of AD
patients. Additionally, the unfolded p53 conformation
was reverted into its wild-type state upon supplementa-
tion of zinc to AD fibroblasts [57]. Although rescue of
p53 conformational changes upon pharmacological and/
or immunological treatment has not been demonstrated
in AD, zinc supplementation can reactivate misfolded
p53 in cancer, making it a potential cancer therapeutic
[76]. Similarly, future studies may investigate whether
restoration of p53 conformation could overcome the
dysregulated p53 signaling in the brain potentially pre-
venting or delaying AD progression.
Conclusions
The balance between the harmful and guarding effects
of p53 is disturbed in various pathologies, including AD
where conformational changes misfold the p53 protein
altering its activity. Although the ramifications of p53
activities in the brain remain to be deciphered, emerging
evidence suggests that dysregulation of its activity may
contribute to various aspects of the pathogenesis of AD.
It is becoming well-established that AD manifests be-
yond the brain, with alterations in the periphery that
could aid in the search for biomarkers of the disease.
The conformational variant of the p53 protein, known as
unfolded p53, could be one of these peripheral bio-
markers, which level was significantly higher in periph-
eral cells derived from patients with AD compared with
non-demented controls, Parkinson’s disease, and other
types of dementia. In addition, misfolding of the p53
protein was found to expose an AD-specific epitope
early on in the disease continuum, holding potential to
predict the conversion from MCI to AD. In summary, a
conformational change in the p53 protein may contrib-
ute to AD exacerbation but holds promise as a potential
peripheral biomarker for early detection of AD.
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